OrbiMed’s Catheter Precision VTAK Stock Holding History

OrbiMed’s Portfolio VTAK Stock Details VTAK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q1	–	Sell	-1	Closed	-$2.78M	–	142
2018 Q4	$2.78M	Hold	1	–	–	0.05%	114
2018 Q3	$5.46M	Buy	+1	New	+$4.54M	0.07%	128

Other funds holding VTAK

BAMCO Inc New York $66.6B AUM 7.35% 1-Year Est. Return

Principal Financial Group Des Moines, Iowa $204B AUM 27.99% 1-Year Est. Return

Neuberger Berman Group New York $150B AUM 40.08% 1-Year Est. Return

Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

ACM

Alethea Capital Management Mercer Island, Washington $241M AUM 112.74% 1-Year Est. Return

SCM

Sio Capital Management New York $604M AUM 96.57% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

MIH

Meitav Investment House Bene-Beraq, Israel $14.9B AUM 46.8% 1-Year Est. Return

OrbiMed's VTAK Position: Q1 2019 in Review

OrbiMed sold out of Catheter Precision (VTAK) in Q1 2019, closing a stake of 1 share — an estimated $2.78M sold.

OrbiMed first reported a position in VTAK in Q3 2018 and held it in 2 quarters. The position peaked at $5.46M in Q3 2018. 9 funds tracked by Wall St. Rank hold VTAK as of Q1 2019.

OrbiMed reported no remaining Catheter Precision position as of Q1 2019 after selling out during the quarter.
OrbiMed sold 1 Catheter Precision share in Q1 2019, an estimated $2.78M.
OrbiMed first reported a position in Catheter Precision in Q3 2018 and held it in 2 quarters.
OrbiMed's Catheter Precision position peaked at $5.46M in Q3 2018.
9 funds tracked by Wall St. Rank held Catheter Precision as of Q1 2019.

Based on OrbiMed's 13F filing for Q1 2019, filed 15 May 2019.